Trial Profile
Effect of TP-452 in dyslipidemia
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2016
Price :
$35
*
At a glance
- Drugs TP 452 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Thetis Pharmaceuticals
- 29 Jan 2016 New trial record
- 27 Jan 2016 According to Thetis Pharmaceuticals media release, company is planning to initiate this study in 2017.